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AbsTrACT
Objective a reperfusion quality of thrombolysis 
in cerebral infarction (TIcI)≥2b has been set as the 
therapeutic angiography target for interventions in patients 
with acute ischaemic stroke. This study addresses whether 
the distinction between TIcI2b and TIcI3 reperfusions 
shows a clinically relevant difference on functional 
outcome.
Methods a systematic literature review and meta-
analysis was carried out and presented in conformity with 
the preferred Reporting Items for systematic Reviews 
and Meta-analyses criteria to test the primary hypothesis 
that TIcI2b and TIcI3 reperfusions are associated with 
different rates of modified Rankin scale (mRs) ≤2 at day 
90. secondary endpoints included rates of haemorrhagic 
transformations, mortality and excellent functional outcome 
(mRs ≤1). summary estimates of ORs (sOR) with 95% cI 
were calculated using the inverse variance heterogeneity 
model accounting for multiple true effect sizes.
results Fourteen studies on 2379 successfully 
reperfused patients were included (1131 TIcI3, 1248 
TIcI2b). TIcI3 reperfusions were associated with higher 
rates of functional independence (1.74, 95% cI 1.44 to 
2.10) and excellent functional outcomes (2.01, 95% cI 
1.60 to 2.53), also after including adjusted estimates. 
The safety profile of patients with TIcI3 was superior, 
as demonstrated by lower rates of mortality (sOR 0.59, 
95% cI 0.37 to 0.92) and symptomatic intracranial 
haemorrhages (sOR 0.42, 95% cI 0.25 to 0.71).
Conclusion TIcI3 reperfusions are associated with 
superior outcome and better safety profiles than TIcI2b 
reperfusions. This effect seems to be independent of 
time and collaterals. as reperfusion quality is the most 
important modifiable predictor of patients’ outcome, 
a more conservative definition of successful therapy 
and further evaluation of treatment approaches geared 
towards achieving TIcI3 reperfusions are desirable.
InTrOduCTIOn
Quality of reperfusion is one of the most important 
and potentially modifiable determinants of clinical 
outcome in patients treated with thrombectomy 
following acute ischaemic stroke.1 It is commonly 
evaluated by applying the five-step thrombolysis in 
cerebral infarction (TICI) grading scale.2 Grades 
2b and 3 are routinely termed ‘successful reperfu-
sion’ as this was shown to be the most favourable 
cut-off for predicting good outcome at 90 days with 
non-significant differences between grades 2b and 
3.3 4 Consequently, the target angiographic endpoint 
has been set to TICI ≥2b.5 However, differences in 
outcome between patients with TICI2b and TICI3 
reperfusions have mostly been neglected, as they 
are often subtle or may have simply been over-
looked, because both grades have been routinely 
subsumed under the term ‘successful’. Recently, 
some studies have suggested superior outcomes for 
TICI3 versus TICI2b reperfusions, thus putting into 
question whether the definition of success should 
be revised.6–8 Due to the relatively small number 
of patients included, it currently remains unclear 
whether the distinction between TICI2b and TICI3 
is clinically relevant. The primary objective of this 
analysis was therefore to identify and quantify all 
available observational data on clinical outcomes 
between TICI2b and TICI3 reperfusions. Further-
more, we aimed to review and discuss recent refine-
ments and modification of the TICI score.
MeThOds
The meta-analysis conducted adheres to the reporting 
guidelines laid down by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
report (PRISMA statement)9 and Meta-analysis 
of Observational Studies in Epidemiology check-
list.10 Several versions of the TICI scale exist and 
are referred to as original, modified or extended 
TICI scale (abbreviated as oTICI, mTICI and eTICI, 
respectively, see online supplementary table I). To 
avoid confusion, oTICI grade 2b is defined as ante-
grade reperfusion of at least two-thirds of the target 
territory.2 mTICI grade 2b refers to antegrade reper-
fusion of at least half of the target territory.5 Grade 
2b in mTICI and eTICI is the same, but an additional 
TICI2c grade has been employed in eTICI referring 
to ‘near complete perfusion except for slow flow in a 
few distal cortical vessels, or presence of small distal 
cortical emboli’.11 12 Lastly, Liebeskind et al recently 
suggested the oTICI2c scale which subdivides the 
grade 2b into 2b with 50%–66% reperfusion and 2b 
with 67%–90% reperfusion. Here, reperfusion of 
90%–99% is referred to as grade 2c13 (see online 
supplementary table I).
Literature search and data extraction
PubMed and Web of Science databases (from incep-
tion to 18 October 2017) were accessed using a 
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predefined search strategy formulated according to the Popu-
lation, Intervention, Comparison and Outcome (PICO) format 
(see online supplementary tables II and III).14 Full-text articles 
and conference abstracts were reviewed. No language restriction 
was applied. Eligibility of the studies for the quantitative anal-
ysis was rated by two independent readers (JK and TD). Studies 
were included into the quantitative synopsis if the study reported 
on (1) the primary outcome stratified according to TICI2b 
versus TICI3 reperfusions or (2) the primary outcome strati-
fied according to TICI2b versus TICI2c/3 reperfusions. Manual 
searching of reference lists of the included studies was coupled 
with a search of all articles citing the included articles using 
Google Scholar metadata (https:// scholar. google. ch/). If avail-
able, TICI2c was pooled together with TICI3, as preliminary 
evidence has suggested that both are associated with a compa-
rable clinical course.15–17 In a sensitivity analysis, comparisons 
of TICI2c/3 and TICI2b were excluded leading to a comparison 
confined to mTICI2b versus mTICI3 in order to rule out the 
possibility that potential differences are only discernible when 
applying the more detailed eTICI scale. Studies that did not meet 
the eligibility criteria but appraised the topic of outcome differ-
ences between TICI2b and TICI3 reperfusions were included 
into further semiquantitative or qualitative analyses.
Primary outcome was the rate of patients achieving func-
tional independence at day 90, defined as modified Rankin 
Scale (mRS) ≤2. Predefined secondary outcomes were excellent 
functional outcome (mRS ≤1), mRS shift, all-cause mortality 
(during hospitalisation or day 90, depending on the reporting 
standards), final infarct volume, rates of symptomatic intracra-
nial haemorrhage (sICH) and rates of any intracranial haemor-
rhage (any ICH). If a study did not report on a clinical definition 
of sICH, rates of parenchymal haematomas (PH1/2 or PH2 
only, depending on the way of reporting) were evaluated as 
radiological surrogate, according to the European Acute Stroke 
Study definiton.18
If available, the following parameters were extracted and 
calculated: type of study, unadjusted odds for the primary and 
secondary outcomes, results from adjusted analyses with a 
description of parameters adjusted for, type of TICI scale applied 
and presence of differences in baseline characteristics. Two inde-
pendent raters extracted the data (JK and MRH). All extracted 
raw frequency counts can be found in the online supplementary 
dataset 1.
statistical analysis
The inverse variance heterogeneity model was used to calculate 
summary estimates of effect sizes (summarised ORs, sOR),19 
since included studies used different inclusion and exclusion 
criteria and require to account for multiple true effect sizes. To 
calculate unadjusted ORs, the prevalence of different endpoints 
was extracted from the published data for each arm. Summarised 
point estimates are displayed together with 95% CIs to express 
the odds for a comparison between TICI3 and TICI2b. Adjusted 
ORs were summarised separately, if available. Heterogeneity was 
explored using Cochrane’s Q and I².20 Visual inspection of funnel 
plots and Doi plots and calculation of the Luis Furuya-Kanamori 
(LFK) index were used for the evaluation of publication bias 
regarding the primary endpoint.21 Data analysis was performed 
using the software package MetaXL (EpiGear International, 
Sunrise Beach, Queensland, Australia) for Microsoft Excel.
risk of bias and quality assessment
The risk of bias was evaluated as per Cochrane Collaboration 
tool.22 Additionally, the following quality criteria were specif-
ically evaluated: (1) specification of inclusion criteria; (2) 
Figure 1 Flow chart according to the preferred Reporting Items for systematic Reviews and Meta-analyses (pRIsMa) recommendations. mRs, modified 
Rankin scale; TIcI, thrombolysis in cerebral infarction. 
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comprehensive reporting of baseline characteristics; (3) avail-
ability of adjusted analyses; and (4) core lab adjudicated reper-
fusion grading. Both ratings were performed independently by 
two readers. In cases of discrepancies a consensus was reached 
(n=6/126 items).
resuLTs
Quantitative analyses
Fourteen studies with a total of 2379 successfully reperfused 
patients (1131 TICI3, 1248 TICI2b) with available follow-up 
were included in the quantitative analysis (see figure 1 for 
PRISMA flow chart).3 7 13 16 17 23–31 During the eligibility rating 
process, five discrepancies arose, which could be resolved by a 
third rater (see online supplementary table IV). Three conference 
abstracts13 27 31 and 11 research articles met the inclusion criteria. 
Eleven of the 14 studies were retrospective observational studies. 
One study examined different degrees of successful reperfu-
sion in the Highly Effective Reperfusion Evaluated in Multiple 
Endovascular Stroke Trials collaboration of recent endovas-
cular trials.13 Eleven studies provided comparisons of mTICI2b 
and mTICI3, one study reported a comparison of mTICI2b 
and mTICI3 together with mTICI2b and mTICI2c/3,17 one 
compared mTICI2b with mTICI2c/3,16 and one study provided 
comparison of TICI2b and TICI2c/3 using the TICI scale revised 
by Liebeskind et al.13 The reporting frequencies and respective 
patient numbers for the primary and secondary endpoints can 
be found in online supplementary table V. An overview of char-
acteristics of the included studies can be found in table 1 and 
online supplementary table VI). The most frequently observed 
differences between patients with TICI2c/3 and TICI2b reper-
fusions were shorter onset to reperfusion metrics and better 
collaterals in the TICI2c/3 group (see table 1). No differences 
regarding the rates of preinterventional intravenous tissue plas-
minogen activator (tPA) administration between both groups 
were reported (see online supplementary table VI).
TICI2c/3 reperfusion was more frequently associated with 
functional independence at day 90 than TICI2b (sOR 1.74, 
95% CI 1.44 to 2.10, figure 2), without substantial heteroge-
neity (I² 13%, Q=15.00, P=0.31). This association remained 
statistically tangible if analysis was confined to studies that used 
Figure 2 summary OR TIcI2c/3 versus TIcI2b for d90 modified Rankin scale (mRs) ≤2. *Used extended TIcI (eTIcI) scale with TIcI2c; TIcI2c and TIcI3 
were subsumed under TIcI3; for grading used in Liebeskind et al see online supplementary table I. TIcI, thrombolysis in cerebral infarction. 
Figure 3 summary OR TIcI2c/3 versus TIcI2b for d90 modified Rankin scale (mRs) ≤1. *Used extended TIcI (eTIcI) scale with TIcI2c; TIcI2c and TIcI3 
were subsumed under TIcI3; for grading used in Liebeskind et al see online supplementary table I. TIcI, thrombolysis in cerebral infarction. 
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the mTICI scale (mTICI3 vs mTICI2b, sOR 1.82, 95% CI 1.41 
to 2.34, online supplementary figure I). Importantly, this asso-
ciation also reached statistical significance after summarising 
the adjusted ORs of the respective studies (adjusted sOR 2.36, 
95% CI 1.69 to 3.30, online supplementary figure II). The overall 
event rate of mRS ≤2 calculated from the studies reviewed 
was ~55%. Assuming this as a reference level, achieving TICI3 
instead of TICI2b in five cases, would result in one additional 
patient reaching functional independence according to the 
adjusted estimates. Furthermore, excellent functional outcomes 
were more commonly observed in patients with TICI2c/3 reper-
fusions (unadjusted sOR 2.01, 95% CI 1.60 to 2.53, adjusted 
sOR 2.70, 95% CI 1.71 to 4.25, figure 3 and online supplemen-
tary figure III, respectively). This was also the case when anal-
ysis was limited to studies using the mTICI scale (mTICI3 vs 
mTICI2b, sOR 2.27, 95% CI 1.67 to 3.08, online supplementary 
figure IV).
TICI2c/3 reperfusion was associated with reduced haemorrhagic 
transformations (sOR 0.48, 95% CI 0.26 to 0.90 for any ICH, 
figure 4A), including symptomatic ICH (sOR 0.42, 95% CI 0.25 to 
0.71, figure 4B, adjusted sOR 0.23, 95% CI 0.11 to 0.48, available in 
two studies). Correspondingly, there was reduced outcome fatality 
in patients in whom TICI2c/3 reperfusion was achieved (sOR 0.59, 
95% CI 0.37 to 0.92, see figure 5). All of the above-mentioned asso-
ciations were also present in an analysis confined to studies applying 
mTICI (mTICI3 vs mTICI2b, data not shown).
No asymmetry was noted for the analyses concerning the rates 
of functional independence at day 90, as revealed by funnel and 
Doi plot inspection (online supplementary figure V). The LFK 
index was indicative of no asymmetry (0.98).
Figure 4 summary OR TIcI2c/3 versus TIcI2b for any intracranial haemorrhage (Ich) and symptomatic intracranial haemorrhage (sIch). (a) any type 
of Ich. (B) symptomatic Ich. §parenchymal haematomas (ph1/2) defined as sIch. *Used extended TIcI (eTIcI) scale with TIcI2c; TIcI2c and TIcI3 were 
subsumed under TIcI3. TIcI, thrombolysis in cerebral infarction. 
Figure 5 summary OR TIcI2c/3 versus TIcI2b for mortality. *Used extended TIcI (eTIcI) scale with TIcI2c; TIcI2c and TIcI3 were subsumed under TIcI3; 
for grading used in Liebeskind et al see online supplementary table I. TIcI, thrombolysis in cerebral infarction. 
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Due to the nature of the topic under review, no study with 
random sequence allocation was available. A substantial risk of 
bias was observed in most studies, however, the most common 
being incomplete outcome data, selective reporting and blinding 
of participants and personnel (online supplementary table VII). 
The most common features reducing the quality of the respec-
tive studies were lack of core lab adjudicated reperfusion grading 
and lack of reporting on adjusted analyses (online supplemen-
tary table VII).
Further semiquantitative and qualitative synopsis
One study provided a comparison of oTICI2b and oTICI3 
patients but was not included because of a significant overlap of 
the study cohort with another analysis.6 16 This article remains 
of interest, however, as it uses the more conservative oTICI scale 
in its definition of grade 2b. Nonetheless, a significant outcome 
difference was present, suggesting that the outcome discrep-
ancies recognised in the above outlined meta-analysis are also 
present when applying the strictest scale.
A recent observational study failed to prove the existence 
of significant outcome differences among TICI3 and TICI2b 
patients when applying the oTICI or mTICI scale, although a 
clear trend was recognisable.15 However, significant differences 
between TICI2c/3 and TICI2b were noted if the eTICI scale 
was applied. The study was excluded from quantitative analyses 
because no dichotomised mRS values were provided.15
One study included in the quantitative analysis group did not 
disclose an adjusted analysis for dichotomised analysis, although 
an ordinal regression analysis was performed. After correction 
for age, sex, pretreatment National Institutes of Health Stroke 
Scale score, target occlusion, infarct core and pretreatment 
alteplase, TICI3 was independently associated with a favourable 
mRS shift at day 90.23
Two of the included studies also provided analyses of tissue 
outcomes. Rangaraju et al27 reported a significant reduction in 
final infarct volume in patients achieving TICI3 as compared 
with TICI2b reperfusion (6.2cc vs 22.5cc, P=0.007). Corrobo-
rating this finding, Chamorro et al reported smaller final infarct 
volumes and reduced infarct growth in patients with TICI3 
reperfusions. Importantly, this association remained statistically 
tangible after the correction for covariates, including infarct core 
on CT perfusion.23
dIsCussIOn
The study-level meta-analysis incorporating data from 2379 
patients provides further evidence that the outcome of patients 
with TICI3 reperfusion is superior to that of patients in whom 
TICI2b reperfusion is achieved. This discrepancy was evident 
from multiple endpoints and even more pronounced when anal-
yses were restricted to adjusted estimates. The observed effect 
remains significant irrespective which TICI score is applied. 
Logically, the better the TICI score, the more tissue is reper-
fused, and the smaller the chance for the penumbra to evolve 
into infarct.32 33 However, the present analysis has substanti-
ated that this specifically holds true also for different degrees of 
successful reperfusion (ie, TICI2b vs TICI3). This implies that 
TICI3 should be reported separately from TICI2b reperfusion in 
all future studies and calls into question whether the definition 
of successful reperfusion should be refined.6 25
Various versions of TICI scales already exist.34 35 So far, the 
three most commonly used are the oTICI,2 the mTICI5 and the 
eTICI with the implementation of grade TICI2c.11 12 All of these 
scales have an acceptable inter-rater reliability.15 36 37 The TICI2c 
score was first mentioned by Noser et al11 and later revisited by 
Goyal et al.12 Its primary intention was to better characterise and 
subcategorise successful reperfusion. So far, substantial evidence 
suggests that patients with a TICI2c reperfusion follow the same 
clinical course as TICI3 patients.15–17 Some TICI2c reperfusions 
would be classified as TICI2b according to the mTICI and oTICI 
systems.15 17 The eTICI systems therefore appear to be the best 
biomarker scale to predict patient outcome more accurately.15 17 
Furthermore, the clinical impact of TICI2b might be influenced 
by the eloquence of the non-reperfused area, a factor currently 
neglected. Distinguishing eloquent (TICI2bE) from non-eloquent 
(TICI2bNE) reperfusion might have added value but may also 
add unnecessary complexity to the scale.
Numerous reasons for successful but incomplete reperfusion 
are conceivable. The most common reason is probably iatrogenic 
distal embolisation during the thrombectomy manoeuver, since 
preinterventional thrombus fragmentation with multiple emboli 
prior to thrombectomy is only rarely observed.38 Another expla-
nation could be microcirculatory failure due to vascular dysreg-
ulation or progressive oedema.39 Another aspect to consider 
is that full parenchymal reperfusion may occur retrogradely 
via well-developed pial collaterals, despite some very distal 
emboli impeding antegrade flow, corresponding to the defini-
tion of eTICI2c, a functional equivalent of TICI3. Numerous 
studies reported that good collaterals favour excellent angio-
graphic results.7 40–42 However, the impact of TICI3 reperfusion 
on outcome seems to be independent of good collaterals and 
independent of time until reperfusion is achieved (cf adjusted 
estimates). Recent evidence from a large registry supports the 
notion that the advancement in technical equipment and oper-
ators’ experience results in increasing rates of TICI3 reperfu-
sions.43 Increasing rates of TICI3 result from protection devices 
and techniques preventing distal embolisation, or due to the 
operators’ dedication to treat remaining distal emboli.6 A recent 
meta-analysis has shown that balloon guiding catheters (BGC) 
increase good angiographic outcomes.44 Moreover, there are 
emerging techniques combining BGC and distal aspiration 
with stent retrievers or stent retriever-assisted vacuum-locked 
extraction of clots aimed at achieving maximum protection.45 46 
Given these results, it seems reasonable that technical efforts 
should be maximised to reduce the risks of periprocedural 
thrombus fragmentation. However, a well-balanced consider-
ation of risks associated with these techniques should be made.
We have not found evidence that pretreatment with intrave-
nous tPA favours achieving TICI3 instead of TICI2b reperfusion, 
as no differences in the rates of intravenous tPA administration 
between TICI2b and TICI2c/3 patients were observed. Results 
from an animal study have suggested a benefit of intravenous 
tPA in reducing downstream microvascular thrombosis during 
large vessel recanalisation.47 However, equal rates of TICI3 
reperfusions between patients treated with direct mechan-
ical thrombectomy and bridging have been reported in recent 
observational studies.48–50 Results from currently enrolling 
randomised controlled trials evaluating direct mechanical throm-
bectomy versus bridging (SWIFT-DIRECT, NCT03192332 and 
MR CLEAN-NO IV, ISRCTN80619088) will provide further 
high-quality evidence regarding the potential value of intrave-
nous tPA regarding this issue.
Additionally, we cannot give a general recommendation to 
treat vascular occlusions causing TICI2b rather than TICI3 
reperfusions only because TICI3 reperfusions are associ-
ated with better outcomes. Although a recent publication has 
addressed the technical feasibility and safety of manoeuvres 
aiming to improve TICI2b reperfusions to TICI3 reperfusions,16 
 o
n
 19 April 2018 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2017-317602 on 8 March 2018. Downloaded from 
7Kaesmacher J, et al. J Neurol Neurosurg Psychiatry 2018;0:1–8. doi:10.1136/jnnp-2017-317602
Cerebrovascular disease
this topic deserves further evaluation in a prospective design. In 
summary, the future direction of research should aim at evalu-
ating strategies to increase the rate of TICI3 reperfusion, the 
ultimate angiographic benchmark of best clinical success and 
outcome.
strengths and limitations
So far, this is the largest pooled patient sample comparing the 
clinical outcome of patients with TICI2b and TICI3 reperfu-
sions. However, this analysis has several limitations, mostly 
reflecting the limitations of the included studies. Most of these 
studies were retrospective observational analyses, giving them 
scope for selection, publication and detection bias. Furthermore, 
most reperfusion statuses were not core lab adjudicated, nor was 
the clinical endpoint assessment blinded. Additionally, outcome 
differences between TICI2b and TICI3 depend on the inclusion 
and exclusion criteria applied at each site. Although we tried to 
account for this heterogeneity using a more conservative statis-
tical approach, we cannot exclude that this affected our analyses. 
Further evaluation derived from large registries may ultimately 
clarify whether core lab evaluated TICI3 vs TICI2b reperfusion 
is as clinically relevant as it appears on outcome and independent 
of potential covariates.
COnCLusIOn
Without considerable heterogeneity and across a wide range 
of clinical and biomarker endpoints analysed, TICI3 reperfu-
sion is associated with superior outcome and safety compared 
with TICI2b. This effect seems to be independent of poten-
tial confounders (eg, time to reperfusion, collaterals). Data 
regarding the interaction and interdependence of these factors, 
however, are sparse. As reperfusion quality is the most important 
modifiable predictor of patient outcome, a more conservative 
definition of therapy success and further evaluation of treat-
ment approaches geared towards achieving TICI3 reperfusions 
by preventing or treating distal emboli more efficiently are 
warranted.
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